

Aducanumab and Research Update

The FDA has approved the use of aducanumab. It is the first new treatment for Alzheimer's disease in 20 years and the very first disease-modifying drug proven to slow AD progression.

Join us to learn about this new medication and the research behind it.



Dr. Sharon Cohen, MD, FRCPC

Medical Director, Toronto Memory Program
Assistant Professor, University of Toronto
Consultant Neurologist, North York General

Wed. Jan. 26th, 2022

7:00pm- 8:15pm

click [here](#) to register

(this is an online event)